While not appropriate for all patients with the myelodysplastic syndrome, recombinant erythropoietin (EPO) is a possible alternative to red blood cell transfusion. Specific factors such as the presence of cytopenias, the bone marrow blast percentage, and cytogenetic findings determine which patients are good candidates for treatment with EPO.
RazaA., GezerS., MundleS.. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.Blood.1995; 86: 268–276.
4.
YoshidaY., AnzaiN., KawabataH.. Apoptosis in myelodysplasia: a paradox or paradigm.Leuk Res.1995; 19: 887–891.
5.
RajapaksaR., GinztonN., RottL.S.. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.Blood.1996; 88: 4275–4287.
6.
AulC., GattermanN., SchneuderW.. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes.Br J Haematol.1992; 82: 358–367.
7.
BennettJ.M., CatovskyD., DanielM.T.. Proposals for the classification of the myelodysplastic syndromes.Br J Haematol.1982; 51: 189–199.
8.
GreenbergP., CoxC., LeBeauM.M.. International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood.1997; 89: 2079–2088.
9.
MuftiG.L.. A guide to risk assessment in the primary myelodysplastic syndrome.Hematol Oncol Clin North Am.1992; 6: 587–606.
10.
RoseE.H., AbelsR.I., NelsonR.A.. The use of r-HUEpo in the treatment of anaemia related to myelodysplasia (MDS).Br J Haematol.1995; 89: 831–837.
11.
Hellström-LindbergE.. Efficacy of erythropoietin in the myelodysplastic syndromes; an analysis of 205 patients in 17 studies.Br J Haematol.1995; 89: 67–71.
12.
Hellström-LindbergE., NegrinR., SteinR.. Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: proposal for a predictive model.Br J Haematol.1997; 99: 344–351.
